Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide.
Fiche publication
Date publication
octobre 2020
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Guillo L, Rabaud C, Choy EH, D'Amico F, Danese S, Ng SC, Peyrin-Biroulet L
Lien Pubmed
Résumé
Herpes zoster is a painful dermatomal cutaneous eruption due to the reactivation of the latent varicella-zoster virus. Patients with inflammatory bowel diseases have an increased risk of shingles compared to the general population and this risk can be increased with the use of immunosuppressive therapy. Live zoster vaccine and recombinant zoster vaccine have demonstrated efficacy for the prevention of herpes zoster. The recombinant zoster vaccine seems to offer greater efficacy and long-term protection profile compared with the life zoster vaccine. However, their use in clinical practice is still unclear and updated vaccination recommendations are lacking. This review will discuss risk for shingles in patients with inflammatory bowel diseases, available vaccines, and their efficacy and safety profiles. We will also provide guidance on who, when, and how to vaccinate for herpes zoster in routine clinical practice amongst patients with inflammatory bowel diseases.
Mots clés
Herpes zoster, Shingrix®, Zostavax®, herpes zoster vaccine, inflammatory bowel diseases, shingles
Référence
Clin Gastroenterol Hepatol. 2020 Oct 17;: